Epigenic Therapeutics
PrivateLast Round
Series B
Sep 7, 2025
Total Funding Raised
$112M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Epigenic Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in September 2025.
Epigenic Therapeutics is a biotechnology company that develops gene-silencing therapies using epigenome regulation and gene editing technology to treat chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epigenic Therapeutics Comparables
Compare Epigenic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moonwalk Biosciences | 88% | |
| Tune Therapeutics | 88% | |
| nChroma Bio | 86% |
For institutional investors. Book with your work email.
Epigenic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 7, 2025 | ||||
| Series A | Aug 30, 2023 | ||||
| Seed | Aug 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Epigenic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| FountainBridge Capital | Seed |
| Lapam Capital | Series B |
| Tigeryeah Capital | Seed |
| OrbiMed | Series B, Series A |
| Trinity Innovation Fund | Seed |
| 5Y Capital | Seed, Series A |
| Qiming Venture Partners | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 41% MoM.
- Sep 7, 2025
$60M round completed.
For institutional investors. Book with your work email.
Epigenic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epigenic Therapeutics's valuation, stock price, and market status.
Is Epigenic Therapeutics a public or private company?
Epigenic Therapeutics is a private company.
What is the current stock price of Epigenic Therapeutics?
Epigenic Therapeutics is a private company, so its shares have no public market price. Caplight tracks Epigenic Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epigenic Therapeutics worth (valuation)?
Valuation information for Epigenic Therapeutics is not publicly available.
Can I buy Epigenic Therapeutics stock?
Epigenic Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epigenic Therapeutics's last funding round?
Epigenic Therapeutics's most recent funding round was Series B on September 7, 2025.
Who are the main investors in Epigenic Therapeutics?
Key investors in Epigenic Therapeutics include Lapam Capital, OrbiMed, Qiming Venture Partners.
Will Epigenic Therapeutics IPO soon?
No public IPO plans have been announced for Epigenic Therapeutics.
How can I track Epigenic Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Epigenic Therapeutics's shares on secondary markets.